Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
Euclid space telescope sees gorgeous cosmic cloud | Space photo of the day for Nov. 18, 2025- Shas threatens to oppose 2026 state budget over haredi food-voucher exclusion
- Reports: Germany plans expansion of foreign intelligence powers
- Novartis to build manufacturing hub in North Carolina, creating 700 jobs
- I’m a dad to an autistic child. Here’s how you can make the holidays easier for all of us.
- Ukraine: Russians abduct 50 Ukrainians from border village in Sumy
- Antivirus Programming for Exhaustive Security
- Ukrainian Army Converts E38 BMW 7-Series Into Multiple Rocket Launch Platform
- Step by step instructions to Pick the Right Dental specialist for Your Teeth Substitution
